JP2025515324A5 - - Google Patents

Info

Publication number
JP2025515324A5
JP2025515324A5 JP2024563219A JP2024563219A JP2025515324A5 JP 2025515324 A5 JP2025515324 A5 JP 2025515324A5 JP 2024563219 A JP2024563219 A JP 2024563219A JP 2024563219 A JP2024563219 A JP 2024563219A JP 2025515324 A5 JP2025515324 A5 JP 2025515324A5
Authority
JP
Japan
Prior art keywords
cancer
reg
composition according
car
granzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024563219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025515324A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/019852 external-priority patent/WO2023211972A1/en
Publication of JP2025515324A publication Critical patent/JP2025515324A/ja
Publication of JP2025515324A5 publication Critical patent/JP2025515324A5/ja
Pending legal-status Critical Current

Links

JP2024563219A 2022-04-28 2023-04-25 がんを処置するためのキメラ抗原受容体改変調節性t細胞 Pending JP2025515324A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263336137P 2022-04-28 2022-04-28
US63/336,137 2022-04-28
PCT/US2023/019852 WO2023211972A1 (en) 2022-04-28 2023-04-25 Chimeric antigen receptor modified regulatory t cells for treating cancer

Publications (2)

Publication Number Publication Date
JP2025515324A JP2025515324A (ja) 2025-05-14
JP2025515324A5 true JP2025515324A5 (cg-RX-API-DMAC10.html) 2026-04-22

Family

ID=86558694

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024563219A Pending JP2025515324A (ja) 2022-04-28 2023-04-25 がんを処置するためのキメラ抗原受容体改変調節性t細胞

Country Status (4)

Country Link
US (1) US20250235478A1 (cg-RX-API-DMAC10.html)
EP (1) EP4514382A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025515324A (cg-RX-API-DMAC10.html)
WO (1) WO2023211972A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025226745A1 (en) * 2024-04-26 2025-10-30 The Regents Of The University Of California Use of rage for priming a treatment for lung cancer and metastases to the lung
WO2025226741A1 (en) * 2024-04-26 2025-10-30 The Regents Of The University Of California Use of rage for targeting cell-based treatments to the lung for the treatment of non-malignant diseases

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
JPH08506247A (ja) 1993-07-09 1996-07-09 アムジェン ボールダー インコーポレイテッド 組換えctla4ポリペプチドおよびその製造方法
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
WO1996027392A1 (en) 1995-03-08 1996-09-12 The Scripps Research Institute Antigen presenting system and methods for activation of t-cells
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
IL126843A (en) 1996-05-23 2007-06-17 Scripps Research Inst Mhc class ii antigen-presenting systems and methods for activating cd4+t cells in vitro
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US5844905A (en) 1996-07-09 1998-12-01 International Business Machines Corporation Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
EP0970128A1 (en) 1997-03-21 2000-01-12 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
BR9907691B1 (pt) 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
US6790662B1 (en) 1999-03-12 2004-09-14 Ortho-Mcneil Pharmaceutical, Inc. Method of isolating CD8+ cells, and related hybridoma cells antibodies and polypeptides
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗cd19抗体
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
EP3053932B1 (en) 2010-02-19 2020-07-22 Xencor, Inc. Novel ctla4-ig immunoadhesins
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012129514A1 (en) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
WO2013071154A1 (en) 2011-11-11 2013-05-16 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
JP2014022858A (ja) 2012-07-17 2014-02-03 Murata Mfg Co Ltd 電力増幅器
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
CN105682683A (zh) 2013-08-02 2016-06-15 阿杜罗生物科技控股有限公司 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
WO2019079034A1 (en) * 2017-10-17 2019-04-25 The General Hospital Corporation METHODS AND COMPOSITIONS RELATING TO GENETICALLY MODIFIED REGULATORY T LYMPHOCYTES
CN107557342A (zh) * 2017-11-02 2018-01-09 广东万海细胞生物科技有限公司 一种CAR‑Treg 细胞的制备方法及其应用
CN114045309A (zh) * 2021-10-28 2022-02-15 郑州赛龙泰克生物科技有限公司 一种通用的嵌合抗原受体调节t细胞制备方法及应用

Similar Documents

Publication Publication Date Title
ES2681948T3 (es) Células de acoplamiento para inmunoterapia
Kozani et al. Novel antigens of CAR T cell therapy: New roads; old destination
JP2024153803A5 (cg-RX-API-DMAC10.html)
Kandalaft et al. Immunotherapy for ovarian cancer: what's next?
Essand et al. Genetically engineered T cells for the treatment of cancer
JP2022545439A5 (cg-RX-API-DMAC10.html)
JP2020127426A5 (cg-RX-API-DMAC10.html)
EP3578570A1 (en) Multifunctional protein
Kang et al. Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced anti-tumor effects
Yamaguchi et al. Adoptive immunotherapy of cancer using activated autologous lymphocytes-current status and new strategies
JP2020534250A5 (cg-RX-API-DMAC10.html)
JP2024153905A (ja) T細胞療法のための診断方法
RU2020127887A (ru) Полипептиды транспозазы и их применение
JP2017531687A5 (cg-RX-API-DMAC10.html)
JP2017522311A5 (cg-RX-API-DMAC10.html)
RU2017114174A (ru) Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии
JP2022532490A5 (cg-RX-API-DMAC10.html)
JP2023513156A5 (cg-RX-API-DMAC10.html)
JP2023082080A5 (cg-RX-API-DMAC10.html)
JP2024520676A5 (cg-RX-API-DMAC10.html)
JP2024531446A5 (cg-RX-API-DMAC10.html)
JP2024546999A5 (cg-RX-API-DMAC10.html)
TWI899236B (zh) 通過投予pd-1抑制劑治療子宮頸癌的方法
JP2022543059A5 (cg-RX-API-DMAC10.html)
Burton et al. Bispecific T-cell engager therapy for gastrointestinal cancers